GLP-1
Compounding
GLP-1
Gonadorelin: The TRT Peptide That Keeps Your Testosterone Axis Alive
Compounding
Compounding Pharmacies and Peptides: 503A vs. 503B, Legal Status, and How to Find a Reputable Source (2026)
Peptides
AOD-9604: Complete Guide to the Growth Hormone Fragment Peptide for Fat Loss (2026)
AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (HGH), specifically amino acids 176 through 191. Originally developed by Monash University in Australia during the late 1990s, AOD-9604 was designed to capture the fat-burning properties of HGH without triggering the hormonal cascade that leads
GLP-1
Compounded Semaglutide in 2026: Legal Status, 503A vs 503B, and What Patients Need to Know
The semaglutide shortage is over and the rules have changed. Here's what patients and prescribers need to know about compounded semaglutide's legal status in 2026 under 503A and 503B.
peptide red flags
10 Red Flags Every Peptide Patient Should Know
Understanding the Peptide Market Landscape The peptide industry has experienced explosive growth over the past decade, driven by compelling preliminary research, social media marketing, and genuine scientific interest in regenerative and performance-enhancing therapies. However, this rapid expansion has created a fragmented marketplace where legitimate clinical practice coexists alongside concerning operations
COA
How to Read a Certificate of Analysis (COA) for Peptides
Understanding the Certificate of Analysis for Peptides A Certificate of Analysis (COA) serves as a quality assurance document that verifies the identity, purity, potency, and safety of a peptide product. Whether you're a healthcare provider ordering peptides from a compounding pharmacy, a researcher evaluating research chemicals, or a
FDA
FDA Peptide Enforcement Actions: What Has Been Banned and Why
Understanding FDA Peptide Enforcement Actions The regulatory landscape for peptides in the United States has undergone significant shifts over the past several years, driven by safety concerns, manufacturing inconsistencies, and the broader challenge of controlling compounded medications. The FDA's enforcement actions against various peptide products reflect an ongoing